The £46bn takeover, the largest by a Japanese company, propelled Takeda into the world's top 10 list of biggest pharmaceutical companies.
GSK - give it time
GlaxoSmithKline's first quarter results were published earlier.
Hyett, Equity Analyst at Hargreaves Lansdown says the company should be given the benefit of the doubt - at least for now.
sales coming in ahead of market expectations is certainly welcome news for GSK,
especially given the headwind presented by generic competition to the group’s
blockbuster asthma treatments in the US. It’s
testament to the strong performance of Glaxo’s vaccines and new respiratory
treatments – both of which have delivered good growth in the key US market.
GSK has again struggled to turn profits into cash, an area where it’s a serial
offender,", he said, with net debt increasing significantly year-on-year.
investors should probably give GSK the benefit of the doubt, at least for now.
The labs are busy, and recent product launches have performed well," he said.